10x Genomics Inc. (TXG)
NASDAQ: TXG
· Real-Time Price · USD
10.80
-0.01 (-0.09%)
At close: Jun 23, 2025, 3:59 PM
11.06
2.36%
Pre-market: Jun 24, 2025, 08:33 AM EDT
10x Genomics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|
| Consumables Revenue | 493.43M | 479.55M | 435.59M | 418.74M | 252.69M | 206.88M |
| Consumables Revenue Growth | +2.89% | +10.09% | +4.02% | +65.72% | +22.14% | n/a |
| Instruments Revenue | 92.72M | 123.47M | 8.43M | 7.28M | 6.03M | 4.07M |
| Instruments Revenue Growth | -24.91% | +1365.53% | +15.79% | +20.62% | +48.21% | n/a |
| Service Revenue | 24.64M | 15.7M | n/a | n/a | n/a | n/a |
| Service Revenue Growth | +56.90% | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|
| Americas Revenue | 347.76M | 373.19M | 46M | 42.09M | 24.51M | 18.21M |
| Americas Revenue Growth | -6.81% | +711.22% | +9.31% | +71.73% | +34.57% | n/a |
| Americas, Excluding United States Revenue | 13.45M | 13.1M | 59.56M | 74.92M | 41.74M | 29.92M |
| Americas, Excluding United States Revenue Growth | +2.64% | -78.00% | -20.51% | +79.50% | +39.51% | n/a |
| Asia Pacific Revenue | 103.26M | 103.26M | 117.07M | 108.49M | 73.27M | 58M |
| Asia Pacific Revenue Growth | 0.00% | -11.80% | +7.91% | +48.08% | +26.31% | n/a |
| Asia-Pacific, Excluding China Revenue | 45.96M | 52.29M | 284.99M | 258.27M | n/a | n/a |
| Asia-Pacific, Excluding China Revenue Growth | -12.12% | -81.65% | +10.34% | n/a | n/a | n/a |
| China Revenue | 57.3M | 50.97M | n/a | n/a | n/a | n/a |
| China Revenue Growth | +12.43% | n/a | n/a | n/a | n/a | n/a |
| Emea Revenue | 159.76M | 142.28M | n/a | n/a | n/a | n/a |
| Emea Revenue Growth | +12.29% | n/a | n/a | n/a | n/a | n/a |
| United States Revenue | 334.32M | 360.09M | n/a | n/a | n/a | n/a |
| United States Revenue Growth | -7.16% | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 89.73M | 93.83M | 81.7M | 83.04M | 84.67M | 86.13M | 82.42M | 91.51M | 83.28M | 78.89M | 73.4M | 79.34M | 66.67M | 69.88M | 62.08M | 68.7M | 56.9M | 55.97M | 51.55M | 44.42M | 50.39M | 38.76M | 32.61M | 32.57M | 26.89M | 26.91M | 19.11M | 21.2M | 20.96M |
| Selling, General, and Administrative Revenue Growth | -4.37% | +14.84% | -1.61% | -1.93% | -1.68% | +4.50% | -9.94% | +9.88% | +5.57% | +7.47% | -7.48% | +18.99% | -4.59% | +12.57% | -9.65% | +20.73% | +1.66% | +8.58% | +16.06% | -11.85% | +30.01% | +18.83% | +0.13% | +21.11% | -0.05% | +40.80% | -9.86% | +1.15% | n/a |
| Research and Development Revenue | 64.25M | 66.97M | 66.17M | 62.92M | 67.94M | 55.55M | 107.91M | 71.46M | 67.1M | 63.61M | 67.29M | 70.69M | 64.08M | 61.88M | 54.58M | 53.4M | 41.88M | 39.7M | 30.14M | 27.54M | 25.99M | 27.89M | 22.21M | 18.03M | 14.96M | 13.08M | 11.09M | 11.44M | 14.79M |
| Research and Development Revenue Growth | -4.07% | +1.20% | +5.17% | -7.39% | +22.30% | -48.52% | +51.01% | +6.50% | +5.48% | -5.46% | -4.80% | +10.31% | +3.55% | +13.38% | +2.21% | +27.50% | +5.49% | +31.72% | +9.47% | +5.94% | -6.80% | +25.58% | +23.15% | +20.51% | +14.41% | +18.00% | -3.14% | -22.62% | n/a |